Sep 30, 2024

Neurocrine Biosciences Q3 2024 Earnings Report

Reported third quarter 2024 financial results and raised 2024 INGREZZA sales guidance.

Key Takeaways

Neurocrine Biosciences reported strong third-quarter 2024 results, driven by a 26% year-over-year increase in INGREZZA sales, reaching $613 million. The company has raised its 2024 INGREZZA sales guidance to $2.30 - $2.32 billion and the Board authorized a $300 million share repurchase plan.

INGREZZA third quarter net product sales were $613 million, representing 26% year-over-year growth.

2024 INGREZZA net product sales guidance raised to $2.30 - $2.32 billion.

Board of Directors authorized a $300 million share repurchase plan.

GAAP net income and earnings per share were $130 million and $1.24, respectively.

Total Revenue
$622M
Previous year: $499M
+24.7%
EPS
$1.81
Previous year: $1.54
+17.5%
R&D Expense
$195M
Previous year: $142M
+37.1%
SG&A Expense
$234M
Previous year: $204M
+14.7%
Gross Profit
$614M
Previous year: $488M
+25.9%
Cash and Equivalents
$1.23B
Previous year: $1.1B
+12.1%
Free Cash Flow
$150M
Previous year: $204M
-26.7%
Total Assets
$3.54B
Previous year: $2.85B
+24.1%

Neurocrine Biosciences

Neurocrine Biosciences

Neurocrine Biosciences Revenue by Segment

Forward Guidance

Neurocrine Biosciences raised its 2024 net sales guidance and updated expense guidance range.

Positive Outlook

  • INGREZZA Net Product Sales are expected to be between $2,300 million and $2,320 million.
  • The company anticipates advancing NBI-1117568 into Phase 3 development in the first half of 2025.
  • Continued investment in INGREZZA, including the expansion of the psychiatry and long-term care sales teams in September 2024.
  • Pre-launch commercial activities for crinecerfont are underway.
  • The Board of Directors authorized a $300 million share repurchase plan.

Challenges Ahead

  • GAAP R&D Expense is projected to be between $700 million and $720 million.
  • Non-GAAP R&D Expense is projected to be between $635 million and $655 million.
  • GAAP SG&A Expense is projected to be between $970 million and $990 million.
  • Non-GAAP SG&A Expense is projected to be between $825 million and $845 million.
  • The ERUDITE Phase 2 study of luvadaxistat in cognitive impairment associated with schizophrenia did not meet its primary endpoint.